Details

Autor(en) / Beteiligte

• Láinez, M. J. A.
• Freitag, F. G.
• Pfeil, J.
• Ascher, S.
• Olson, W. H.
• Schwalen, S.

Titel

Time course of adverse events most commonly associated with topiramate for migraine prevention

Ist Teil von

• European journal of neurology, 2007-08, Vol.14 (8), p.900-906

Ort / Verlag

Oxford, UK: Blackwell Publishing Ltd

Erscheinungsjahr

2007

Quelle

MEDLINE

Beschreibungen/Notizen

• The efficacy, safety and tolerability of topiramate has been demonstrated in three large multicenter, randomized, double‐blind, placebo‐controlled trials. To characterize the time course of adverse events (AEs) that led to treatment discontinuation in ≥2% of patients who received topiramate 100 mg/day during three pivotal, multicenter, randomized, double‐blind, placebo‐controlled, and 26‐week trials. The pooled population comprised all randomized patients who reported safety data during the double‐blind phase (topiramate 100 mg/day, n = 386; placebo n = 372), which consisted of a 4‐week titration period and a 22‐week maintenance period. Incidence, time to onset, and cumulative mean rate of AEs were assessed. Overall, AEs led to treatment discontinuation in 24.9% of patients receiving topiramate 100 mg/day and 11.0% receiving placebo (P < 0.001). AEs leading to discontinuation during the double‐blind phase in ≥2% of patients included paresthesia (8.0% discontinued), any cognitive symptoms (7.3% discontinued), fatigue (4.7% discontinued), insomnia (3.4% discontinued), nausea (2.3% discontinued), loss of appetite, anxiety, and dizziness (2.1% discontinued because each AE). Most AEs began during the titration period. Paresthesia, any cognitive symptoms, nausea, and loss of appetite occurred at a higher rate in the topiramate group than in the placebo group (P < 0.01). AEs leading to discontinuation of topiramate are probably to occur during dose titration. If a patient has not experienced one of these AEs within the first 6 weeks of initiating topiramate 100 mg/day, these AEs are unlikely to occur.